Immune biomarkers for prognosis and prediction of responses to immune checkpoint blockade in cutaneous melanoma

OncoImmunology

Nicolas Jacquelot¹  Connie P. M. Duong¹  Laurence Zitvogel¹  Maria Paula Roberti¹  Sylvie Rusakiewicz¹  Jonathan M. Pitt¹  David P. Enot²  Alexander M. Eggermont³ 

[1] Université Paris-Saclay, INSERM U1015;Université Paris-saclay, Metabolomics and Cell Biology Platforms;Université Paris-saclay;

关键词: immune biomarkers;    immunotherapy;    melanoma;    predictive factors;    prognostic factors;   

DOI  :  10.1080/2162402X.2017.1299303

来源: DOAJ

【 摘 要 】

Existing clinical, anatomopathological and molecular biomarkers fail to reliably predict the prognosis of cutaneous melanoma. Biomarkers for determining which patients receive adjuvant therapies are needed. The emergence of new technologies and the discovery of new immune populations with different prognostic values allow the immune network in the tumor to be better understood. Importantly, new molecules identified and expressed by immune cells have been shown to reduce the antitumor immune efficacy of therapies, prompting researchers to develop antibodies targeting these so-called “immune checkpoints”, which have now entered the oncotherapeutic armamentarium.

【 授权许可】

Unknown